|Videos|June 20, 2017

How Preventable are Clostridium difficile Infections?

Gonzalo Bearman, MD, MPH, explains what is known about Clostridium difficile prevention and control.

Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, explains what is known about Clostridium difficile prevention and control.

Interview Transcript (slightly modified for readability)

“The extent to which C. difficile is preventable is still highly debatable. For example, the science of infection control can prevent central line-associated bloodstream infections much more effectively than C. difficile. We can prevent catheter-associated [urinary tract infections] much more effectively than C. difficile.

Much of C. difficile is probably coming from diverse reservoirs, it’s probably coming from the community and the environment and not necessarily hospital-acquired. So, the degree to which we can stop the transmission or alter the development of disease is still not well-defined.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.